Muscle-specific kinase antibody positive myaesthenia gravis and multiple sclerosis co-presentation: A case report and literature review

Journal of Neuroimmunology

Volumn 264, Issue 1-2, 2013, Pages 130-133

  Sylvester, Jessica ^a   Purdie, Grant ^b   Slee, Mark ^c   Gray, James X ^b   Burnet, Simon ^b   Koblar, Simon ^d  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Demyelination; Multiple sclerosis; Muscle specific kinase antibody; Myaesthenia gravis

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; C REACTIVE PROTEIN; ENZYME ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; MUSCLE SPECIFIC KINASE ANTIBODY; PREDNISOLONE; PYRIDOSTIGMINE; RITUXIMAB; STEROID; UNCLASSIFIED DRUG;

ADULT; AMNESIA; ANTIBODY DETECTION; ARTICLE; BLURRED VISION; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; COMORBIDITY; DIARRHEA; DIPLOPIA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TOLERABILITY; DYSARTHRIA; DYSPHAGIA; DYSPHONIA; DYSPNEA; EVOKED VISUAL RESPONSE; FATIGUE; GAIT DISORDER; GASTROESOPHAGEAL REFLUX; HEMIPARESIS; HUMAN; INVOLUNTARY MOVEMENT; LETHARGY; LIMB WEAKNESS; LOW DRUG DOSE; MALE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYOCLONUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOPLEGIA; PHONOPHOBIA; POLYARTHRITIS; PRIORITY JOURNAL; PTOSIS; SLURRED SPEECH; TRANSIENT ISCHEMIC ATTACK;

DEMYELINATION; MULTIPLE SCLEROSIS; MUSCLE-SPECIFIC KINASE ANTIBODY; MYAESTHENIA GRAVIS;

AUTOANTIBODIES; BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84886794953     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.08.016     Document Type: Article

References (16)

1. Barun B., Bar-Or A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin. Immunol. 2012, 142:31-37.
2. Basiri K., Etemadifar M., Maghzi A.H., Zarghami N. Frequency of myasthenia gravis in multiple sclerosis: report of five cases from Isfahan, Iran. Neurol. India 2009, 57:638-640.
3. Bhagavati S., Maccabee P.J., Chari G. Is cerebral involvement an occasional feature of muscle-specific kinase antibody-positive syndrome?. Eur. J. Neurol. 2007, 14:e21-e22.
4. Diaz-Manera J., Martinez-Hernandez E., Querol L., Klooster R., Rojas-Garcia R., Suarez-Calvet X., Munoz-Blanco J.L., Mazia C., Straasheijm K.R., Gallardo E., Juarez C., Verschuuren J.J., Illa I. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012, 78:189-193.
5. Furukawa Y., Yoshikawa H., Yachie A., Yamada M. Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population. Eur. J. Neurol. 2006, 13:655-658.
6. Garcia-Osta A., Tsokas P., Pollonini G., Landau E.M., Blitzer R., Alberini C.M. MuSK expressed in the brain mediates cholinergic responses, synaptic plasticity, and memory formation. J. Neurosci. 2006, 26:7919-7932.
7. Gotkine M., Fellig Y., Abramsky O. Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology 2006, 67:881-883.
8. Guptill J.T., Sanders D.B. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr. Opin. Neurol. 2010, 23:530-535.
9. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H., Group H.T. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
10. Isbister C.M., Mackenzie P.J., Anderson D., Wade N.K., Oger J. Co-occurrence of multiple sclerosis and myasthenia gravis in British Columbia. Mult. Scler. 2003, 9:550-553.
11. Ito K., Mizutani J., Murofushi T., Mizuno M. Bilateral pseudo-internuclear ophthalmoplegia in myasthenia gravis. ORL J. Otorhinolaryngol. Relat. Spec. 1997, 59:122-126.
12. Lanfranconi S., Corti S., Baron P., Conti G., Borellini L., Bresolin N., Bersano A. Anti-MuSK-positive myasthenia gravis in a patient with Parkinsonism and cognitive impairment. Neurol. Res. Int. 2011, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148447/.
13. Pasnoor M., Wolfe G.I., Nations S., Trivedi J., Barohn R.J., Herbelin L., Mcvey A., Dimachkie M., Kissel J., Walsh R., Amato A., Mozaffar T., Hungs M., Chui L., Goldstein J., Novella S., Burns T., Phillips L., Claussen G., Young A., Bertorini T., Oh S. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 2010, 41:370-374.
14. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'Connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
15. Somer H., Muller K., Kinnunen E. Myasthenia gravis associated with multiple sclerosis. Epidemiological survey and immunological findings. J. Neurol. Sci. 1989, 89:37-48.
16. Vaknin-Dembinsky A., Abramsky O., Petrou P., Ben-Hur T., Gotkine M., Brill L., Brenner T., Argov Z., Karussis D. Myasthenia gravis-associated neuromyelitis optica-like disease: an immunological link between the central nervous system and muscle?. Arch. Neurol. 2011, 68:1557-1561.